DNTH
Dianthus Therapeutics, Inc. /de/ Health Care Pharmaceutical Preparations Russell 3000
$82.38Close
$3.6BMarket cap
$33.20 – $115.9652-week range
Nov 4, 2026Next report
Highlights
Strengths
- Leading the market RS 85 · stronger than 85% of stocks over 12 months
Cautions
- Not in an uptrend 4 of 8 trend conditions
- Far from its high 29% below its 52-week high
- Distribution down-day volume 1.7× up-day volume over 50 sessions
- Results soon Nov 4, 2026, in 3 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
29%
1wk
up 7.3%
price change
1mo
down 6.4%
price change
12-month return
up 144%
market up 11% ·
its own up 133%
F-score
—
— Not assessed
Altman Z
55.81
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
7.2×
price / book
Earnings yield
down 5.1%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
down 67%
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 38%
return on equity
Free cash margin
down 6339%
-$129.1M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.8%
$3.99 a day · 2×ATR $74.40
RS
85 / 99
vs the universe
Trend
4 / 8
trend template
Relative volume
0.6×
vs 50-day average
Up/down volume
0.58
50 sessions
Implied move
—
no option chain · report Nov 4, 2026
Trend template · 4 of 8
- Price above the 150 and 200-day averages: fails
- 150-day average above the 200-day: passes
- 200-day average rising for a month: passes
- 50-day average above the 150 and 200-day: fails
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: passes
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 38.9% over the year, from 31m to 43m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 67.3% over the year, from $6.2M to $2.0M.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026+5% vs market2 sessions after results
Financials
- Net -7973%
- Free cash -6339%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | — | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Operating income | -$78.7M | -$13.1M | -$29.7M | -$48.2M | -$101.9M | -$177.9M |
| Net income | -$74.9M | -$13.1M | -$28.5M | -$43.5M | -$85.0M | -$162.3M |
| Net margin | — | -888% | -444% | -1541% | -1363% | -7973% |
| Earnings per share | -$1.71 | -$15.01 | -$32.57 | -$8.45 | -$2.55 | -$4.20 |
| Free cash flow | -$64.4M | -$11.2M | -$29.4M | -$36.9M | -$78.2M | -$129.1M |
| Free cash margin | — | -757% | -458% | -1304% | -1254% | -6339% |
| Cash | $58.2M | $7.6M | $15.4M | $132.3M | $22.8M | $51.1M |
| Shareholders' equity | -$4.2M | -$17.2M | -$44.4M | $168.9M | $352.5M | $493.4M |
| Shares outstanding | 48.53m | 875.28k | 875.28k | 14.82m | 31.12m | 43.22m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Mar 9, 2026 | Annual ↗ | Dec 31, 2025 | 68d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 7, 2025 | Quarterly ↗ | Jun 30, 2025 | 38d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 11, 2025 | Annual ↗ | Dec 31, 2024 | 70d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 8, 2024 | Quarterly ↗ | Jun 30, 2024 | 39d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 21, 2024 | Annual ↗ | Dec 31, 2023 | 81d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 4, 2026 | Results ↗ |
| Jun 12, 2026 | Other events ↗ |
| May 22, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Mar 26, 2026 | Other events ↗ |
| Mar 12, 2026 | Material agreement ↗ |
| Mar 9, 2026 | Results · Regulation FD · Other events ↗ |
| Jan 12, 2026 | Results · Regulation FD ↗ |
| Nov 5, 2025 | Results ↗ |
| Nov 3, 2025 | Other events ↗ |
| Oct 16, 2025 | Material agreement · Results · Other events ↗ |
| Sep 11, 2025 | Material agreement ↗ |